抗菌薬耐性診断市場：製品タイプ、検査場所、施設タイプ別-世界予測2025-2030年

抗菌薬耐性診断市場は、2023年に45億3,000万米ドルと評価され、2024年には47億5,000万米ドルに達すると予測され、CAGR 6.14％で成長し、2030年には68億8,000万米ドルに達すると予測されています。

抗菌薬耐性（AMR）診断市場には、病原体の耐性パターンを特定し、治療の意思決定に役立てることを目的とした技術や製品が含まれます。これには分子検査、イムノアッセイ、迅速診断キットなどが含まれます。これらの診断の必要性は、公衆衛生上の重大な課題である薬剤耐性感染症の蔓延の増加によって強調されています。AMR診断薬は、適切な抗生物質使用の指針となる臨床現場と、世界の耐性パターンの追跡に役立つ公衆衛生サーベイランスの双方において重要です。同市場は、病院、診療所、研究所、学術機関、研究機関など、さまざまなエンドユーザーにサービスを提供しています。大きな成長要因としては、AMR問題に対する意識の高まり、政府の取り組み、診断技術の進歩、抗生物質の誤用や過剰使用を減らす必要性などが挙げられます。ポイントオブケア診断の急速な発展と診断プロセスへのAIの統合は、利害関係者に有望な機会をもたらしています。しかし、先進的な診断機器の高コスト、規制上のハードル、特に低所得地域におけるインフラ投資の必要性などの課題も残っています。資源が限られた環境に適した、費用対効果が高く、使いやすいポイント・オブ・ケア機器の開発に主な成長機会が存在します。さらに、包括的な耐性プロファイルを迅速に提供できる次世代シーケンス技術の開発にも可能性があります。企業は、世界のヘルスケアのニーズに合致した、迅速で費用対効果の高い診断薬のイノベーションを優先すべきです。官民の協力関係を強化することで、研究開発努力を強化し、市場範囲を拡大することができます。同市場は大きな可能性を秘めているが、経済的な制約から物流上の障壁や一部の地域での普及率の遅れが成長の妨げとなる可能性があります。そのため、AMR診断薬の利点についてヘルスケアプロバイダーを教育し、普及を促進するための意識向上プログラムを作成することに注力することは戦略的であると考えられます。全体として、パートナーシップの構築、最先端技術への投資、地域特有の課題への取り組みが、市場の発展にとって極めて重要です。

市場力学：急速に進化する抗菌薬耐性診断市場の主要市場インサイトを公開

抗菌薬耐性診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 診断ソリューションの需要拡大につながる抗菌薬耐性の蔓延の増加
  • 診断法の改善を通じて抗菌薬耐性と闘うための政府の取り組みと資金援助
  • 早期かつ正確な抗菌薬耐性診断の重要性に対するヘルスケア専門家や一般市民の意識の高まり
• 市場抑制要因
  • 高度な診断検査に伴う高コスト
• 市場機会
  • 包括的な診断アプローチを用いて抗菌薬耐性と闘うためのセクターを超えたパートナーシップ
  • 抗菌薬耐性診断イノベーションに注力する新興企業への投資機会
• 市場の課題
  • 様々な地域における標準化プロトコルと規制の調和の欠如

ポーターの5つの力：抗菌薬耐性診断市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、抗菌薬耐性診断市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗菌薬耐性診断市場における外部からの影響の把握

外部マクロ環境要因は、抗菌薬耐性診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析抗菌薬耐性診断市場における競合情勢の把握

抗菌薬耐性診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス抗菌薬耐性診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗菌薬耐性診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨抗菌薬耐性診断市場における成功への道筋を描く

抗菌薬耐性診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 抗菌薬耐性の蔓延により診断ソリューションの需要が増加
    • 診断の改善を通じて抗菌薬耐性と闘うための政府の取り組みと資金提供
    • ヘルスケア従事者と一般の人々の間で、抗菌薬耐性の早期かつ正確な診断の重要性についての認識が高まっています。
  • 抑制要因
    • 高度な診断検査に伴う高コスト
  • 機会
    • 包括的な診断アプローチを用いた抗菌薬耐性と闘うための分野横断的なパートナーシップ
    • 抗菌薬耐性診断イノベーションに重点を置いたスタートアップへの投資機会
  • 課題
    • さまざまな地域における標準化プロトコルと規制の調和の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 抗菌薬耐性診断市場：製品タイプ別

• アッセイと試薬
  • バイオセンサー
  • モノクローナル抗体
• 診断ツール
  • 機器
  • ソフトウェアとサービス

第7章 抗菌薬耐性診断市場試験場所別

• 臨床検査
  • 等温核酸増幅技術（INAAT）
  • ポリメラーゼ連鎖反応（PCR）
• ポイントオブケア検査
  • 免疫測定
  • マイクロアレイ

第8章 抗菌薬耐性診断市場施設タイプ別

• エンドユーザー
  • 診断検査室
  • 病院と診療所
• 調査
  • CRO
  • 調査機関

第9章 南北アメリカの抗菌薬耐性診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の抗菌薬耐性診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの抗菌薬耐性診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Abbott Laboratories
• 2. Accelerate Diagnostics
• 3. Beckman Coulter
• 4. Becton, Dickinson and Company
• 5. BioFire Diagnostics
• 6. bioMerieux
• 7. Bruker Corporation
• 8. Cardinal Health
• 9. Cepheid
• 10. GenMark Diagnostics
• 11. GSK plc
• 12. Hoffmann-La Roche
• 13. Hologic, Inc.
• 14. Luminex Corporation
• 15. Merck & Co., Inc.
• 16. OpGen
• 17. Qiagen
• 18. Siemens Healthineers
• 19. T2 Biosystems
• 20. Thermo Fisher Scientific

LIST OF FIGURES

• FIGURE 1. ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET RESEARCH PROCESS
• FIGURE 2. ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MONOCLONAL ANITBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 62. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 64. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 65. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 66. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 67. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 68. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. CANADA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. AUSTRALIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 109. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 111. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 112. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 113. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 114. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 115. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. CHINA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 118. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 120. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 121. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 122. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 123. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 124. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. INDIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 132. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 133. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. INDONESIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 139. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 140. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 141. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 142. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. JAPAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 147. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 148. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 149. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 150. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 151. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. MALAYSIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 156. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 157. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 158. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 159. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 160. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. PHILIPPINES ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 163. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 165. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 166. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 167. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 168. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 169. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. SINGAPORE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 172. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 174. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 175. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 178. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. SOUTH KOREA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 181. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 183. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 184. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 185. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 186. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 187. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. TAIWAN ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 190. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 192. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 193. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 194. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 195. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 196. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 197. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. THAILAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 199. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 200. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 201. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 202. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 203. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 204. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 205. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. VIETNAM ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 218. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 220. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 221. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 222. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 223. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 224. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 225. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. DENMARK ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 227. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 228. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 229. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 230. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 231. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 232. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 233. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 234. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. EGYPT ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 236. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 238. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 239. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 240. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 241. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 242. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 243. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 244. FINLAND ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 245. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 246. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 247. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 248. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 249. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 250. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 251. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 253. FRANCE ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 254. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 255. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 256. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 257. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 258. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 259. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 260. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 261. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 262. GERMANY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 263. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 264. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 265. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 266. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 267. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 268. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 269. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 271. ISRAEL ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 272. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 273. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 274. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 275. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 276. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 277. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 278. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 279. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 280. ITALY ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 281. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 282. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 283. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
• TABLE 284. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
• TABLE 285. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
• TABLE 286. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
• TABLE 287. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY FACILITY TYPE, 2018-2030 (USD MILLION)
• TABLE 288. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 289. NETHERLANDS ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 290. NIGERIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 291. NIGERIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MARKET SIZE, BY ASSAYS & REAGENTS, 2018-2030 (USD MILLION)
• TABLE 292. NIGERIA ANTIMICROBIAL RESISTANCE DIAGNOSTIC MAR

The Antimicrobial Resistance Diagnostic Market was valued at USD 4.53 billion in 2023, expected to reach USD 4.75 billion in 2024, and is projected to grow at a CAGR of 6.14%, to USD 6.88 billion by 2030.

The antimicrobials resistance (AMR) diagnostics market encompasses technologies and products aimed at identifying resistance patterns in pathogens to inform treatment decisions. This includes molecular tests, immunoassays, and rapid diagnostic kits. The necessity for these diagnostics is underscored by the rising prevalence of drug-resistant infections, which pose substantial public health challenges. AMR diagnostics are critical in both clinical settings-where they guide appropriate antibiotic usage-and in public health surveillance, helping track resistance patterns worldwide. The market serves various end-users, including hospitals, clinics, laboratories, academic institutions, and research organizations. Significant growth factors include increasing awareness of AMR issues, governmental initiatives, advancements in diagnostic technologies, and the necessity to reduce misuse and overuse of antibiotics. The rapid development of point-of-care diagnostics and integration of AI in diagnostic processes present promising opportunities for stakeholders. However, challenges persist, including high costs of advanced diagnostic equipment, regulatory hurdles, and the need for investment in infrastructure, particularly in low-income regions. Key growth opportunities exist in developing cost-effective, easy-to-use point-of-care devices suitable for resource-limited settings. Moreover, there is potential in the development of next-generation sequencing technologies that can provide comprehensive resistance profiles swiftly. Businesses should prioritize innovation in rapid, cost-effective diagnostics, which align with global healthcare needs. Increasing collaboration between public and private sectors can enhance research and development efforts, thus expanding market reach. While the market offers robust potential, its growth can be stymied by logistical barriers and the slow adoption rate in some regions due to economic constraints. Therefore, focusing on educating healthcare providers about the benefits of AMR diagnostics and creating awareness programs to enhance adoption could be strategic. Overall, forging partnerships, investing in cutting-edge technology, and addressing region-specific challenges are pivotal for market advancement.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimicrobial Resistance Diagnostic Market

The Antimicrobial Resistance Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of antimicrobial resistance leading to a higher demand for diagnostic solutions
  • Government initiatives and funding to combat antimicrobial resistance through improved diagnostics
  • Growing awareness among healthcare professionals and public about the importance of early and accurate antimicrobial resistance diagnosis
• Market Restraints
  • High cost associated with advanced diagnostic tests
• Market Opportunities
  • Cross-sector partnerships to combat antimicrobial resistance using comprehensive diagnostic approaches
  • Investment opportunities in startups focused on antimicrobial resistance diagnostic innovations
• Market Challenges
  • Lack of standardization protocol and regulatory harmonization across various region

Porter's Five Forces: A Strategic Tool for Navigating the Antimicrobial Resistance Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimicrobial Resistance Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimicrobial Resistance Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimicrobial Resistance Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimicrobial Resistance Diagnostic Market

A detailed market share analysis in the Antimicrobial Resistance Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimicrobial Resistance Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimicrobial Resistance Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimicrobial Resistance Diagnostic Market

A strategic analysis of the Antimicrobial Resistance Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Resistance Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Beckman Coulter, Becton, Dickinson and Company, BioFire Diagnostics, bioMerieux, Bruker Corporation, Cardinal Health, Cepheid, GenMark Diagnostics, GSK plc, Hoffmann-La Roche, Hologic, Inc., Luminex Corporation, Merck & Co., Inc., OpGen, Qiagen, Siemens Healthineers, T2 Biosystems, and Thermo Fisher Scientific.

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Resistance Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Assays & Reagents and Diagnostic Tools. The Assays & Reagents is further studied across Biosensors and Monoclonal Anitbodies. The Diagnostic Tools is further studied across Instruments and Software & Services.
• Based on Testing Location, market is studied across Laboratory Testing and Point-Of-Care Testing. The Laboratory Testing is further studied across Isothermal Nucleic Acid Amplification Technology (INAAT) and Polymerase Chain Reaction (PCR). The Point-Of-Care Testing is further studied across Immunoassays and Microarray.
• Based on Facility Type, market is studied across End User and Research. The End User is further studied across Diagnostic Laboratories and Hospitals And Clinics. The Research is further studied across CROs and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of antimicrobial resistance leading to a higher demand for diagnostic solutions
    • 5.1.1.2. Government initiatives and funding to combat antimicrobial resistance through improved diagnostics
    • 5.1.1.3. Growing awareness among healthcare professionals and public about the importance of early and accurate antimicrobial resistance diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with advanced diagnostic tests

• 5.1.3. Opportunities
  • 5.1.3.1. Cross-sector partnerships to combat antimicrobial resistance using comprehensive diagnostic approaches
  • 5.1.3.2. Investment opportunities in startups focused on antimicrobial resistance diagnostic innovations
• 5.1.4. Challenges
  • 5.1.4.1. Lack of standardization protocol and regulatory harmonization across various region
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antimicrobial Resistance Diagnostic Market, by Product Type

• 6.1. Introduction
• 6.2. Assays & Reagents
  • 6.2.1. Biosensors
  • 6.2.2. Monoclonal Anitbodies
• 6.3. Diagnostic Tools
  • 6.3.1. Instruments
  • 6.3.2. Software & Services

7. Antimicrobial Resistance Diagnostic Market, by Testing Location

• 7.1. Introduction
• 7.2. Laboratory Testing
  • 7.2.1. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.2.2. Polymerase Chain Reaction (PCR)
• 7.3. Point-Of-Care Testing
  • 7.3.1. Immunoassays
  • 7.3.2. Microarray

8. Antimicrobial Resistance Diagnostic Market, by Facility Type

• 8.1. Introduction
• 8.2. End User
  • 8.2.1. Diagnostic Laboratories
  • 8.2.2. Hospitals And Clinics
• 8.3. Research
  • 8.3.1. CROs
  • 8.3.2. Research Institutes

9. Americas Antimicrobial Resistance Diagnostic Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Antimicrobial Resistance Diagnostic Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Antimicrobial Resistance Diagnostic Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Accelerate Diagnostics
• 3. Beckman Coulter
• 4. Becton, Dickinson and Company
• 5. BioFire Diagnostics
• 6. bioMerieux
• 7. Bruker Corporation
• 8. Cardinal Health
• 9. Cepheid
• 10. GenMark Diagnostics
• 11. GSK plc
• 12. Hoffmann-La Roche
• 13. Hologic, Inc.
• 14. Luminex Corporation
• 15. Merck & Co., Inc.
• 16. OpGen
• 17. Qiagen
• 18. Siemens Healthineers
• 19. T2 Biosystems
• 20. Thermo Fisher Scientific